CD4 and COVID-19: However, the analysis of the CD3low populations revealed WT S-reactive CD4+ T cells with higher avidity among the COVID-19 cohort compared to the VBI patients, suggesting there is no vaccination advantage among the VBI cohort (Figure 4B).